Egyptian Hypertrophic Cardiomyopathy Program
ConditionHypertrophic Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMagdi Yacoub Heart Foundation
About this trial
Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
All patients diagnosed with hypertrophic cardiomyopathy (index patients) who are willing and consented to participate in the registry.
All family members of index patients who are willing and consented to participate in the registry.
Disqualifiers
Refusal to consent to participate in the registry program.
Trial population
Egyptian patients diagnosed with hypertrophic cardiomyopathy (either obstructive or non-obstructive), and their family members (either apparently healthy or not) who are willing to participate in this registry.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Incidence of HCM in Egypt
per 100,000 population per year
Time frame
through study completion, an average of 5 year2
Determinants of clinical severity of HCM in Egypt
Several indicators describing the clinical symptoms and signs
Time frame
through study completion, an average of 1 follow-up every year, and an average of 5 follow-ups throughout the study duration3
Determinants of cardiac phenotype severity of HCM in Egypt
Several indicators describing the cardiac phenotype using multimodality imaging
Time frame
through study completion, an average of 1 follow-up every year, and an average of 5 follow-ups throughout the study duration4
Determinant of genotype severity of HCM in Egypt
To identify and report the genetic profile of HCM in Egypt.
Time frame
through study completion, at least once at the time of inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov